Skip to main content
CRONCronos Group Inc. Common ShareHold6.2·$3.35
HoldModerate Confidence
Investment thesis

Cronos Group shows genuine 40% YoY revenue growth, a strong Piotroski F-Score, and bullish above-200-day-MA technicals, but a quality score below the engine's minimum floor and a deeply negative asymmetry ratio drive an explicit exit recommendation.

Thesis pillars

  • Revenue Growth Leadership→Stable
  • Piotroski Quality Signal→Stable
  • Negative Asymmetry Target Reached→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Feb 26, 2026

Full reasoning →

Open full analysis

Cronos Group Inc. Common Share (CRON) Stock Analysis

Breakout setup

HoldValueGrowthQualityModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Earnings in 6 days (2026-11-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $3.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).

Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor... Read more

QualityF-score6 / 9FCF yield0.49%
Stop $3.17Analyst target $2.56(reached)A.R:R -3.9:1
Analyst consensus$3.01-10.0%1 analysts
Range unavailable (1 analysts)

Hold if already holding. Not a fresh buy at $3.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Mixed signals. Hold existing position. Score 6.2/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.

10-K grounded · weekly refresh

About Cronos Group Inc. Common Share

About Cronos Group Inc. Common Share

Cronos Group sells cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands from a single reporting segment spanning licensed production in Canada and Israel. Two customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Cronos sold $122.4 million of product to Canadian cannabis control authorities during the year.

Cronos cultivates and processes cannabis at the Peace Naturals Campus in Ontario and through Cronos GrowCo, a 50%-owned joint venture over whose board Cronos gained majority control in July 2024 and which the company describes as its principal cannabis source; Cronos holds the right, but not the obligation, to purchase up to 70% of GrowCo's total production. In Israel, Cronos Israel distributes PEACE NATURALS and LIT medical cannabis through pharmacies under IMC-GAP, IMC-GMP, and IMC-GDP certifications, and the company has expanded LIT and Lord Jones distribution into Germany and the United Kingdom through third-party partners. Altria Group beneficially owned 41.0% of Cronos common shares as of December 31, 2025 and holds board-nomination, approval, and pre-emptive rights under an investor rights agreement tied to its ownership threshold.

Show full overview

Cronos does not engage in any U.S. Schedule I cannabis activity, insulating it from federal enforcement risk that touches U.S.-domiciled operators, even after President Trump's December 18, 2025 executive order directed the Attorney General to expedite rescheduling marijuana to Schedule III — a change that would not take effect until the required federal rulemaking process concludes. Government-channel dependency is the more immediate exposure: Canadian sales flow through provincial cannabis control authorities that can renegotiate prices or terminate supply agreements at their election, concentrating Cronos's two largest customer relationships within government-run distribution monopolies rather than diversified retail accounts.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Cronos Group Inc. Common Share's most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 20266d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong growth profile
Outperforming peers
Risks
Analyst target reached - limited upside remaining
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7)
Earnings in 6 days (event risk)

Key Metrics

P/E (TTM)17.6
P/E (Fwd)-83.8
Mkt Cap$1.2B
EV/EBITDA41.0
Profit Mgn39.1%
ROE7.0%
Rev Growth58.4%
Beta1.20
DividendNone
Rating analysts9

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C1.00neutral
IV87%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerOntario Cannabis Retail Corporation27%
    10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'
  • LOWCustomerAlberta Gaming, Liquor and Cannabis Commission16%
    10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 ceiling hit

GatesA.R:R -3.9=NEGATIVEEARNINGS PROXIMITY 6d<=7dMomentum 4.5<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.5>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
61 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $3.15Resistance $3.46

Price Targets

A.Upside-23.5%
A.R:R-3.9:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeRisk-Off

Risk Alerts

! Target reached (-23.5% upside)
! Negative risk/reward — downside exceeds upside
! EARNINGS_PROXIMITY:6d<=7d

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-11-05 (6d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CRON stock a buy right now?

Hold if already holding. Not a fresh buy at $3.35, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Mixed signals. Hold existing position. Analyst target $2.56 reached (−23.5%), stop $3.17 (−5.7%), A.R:R -3.9:1. Score 6.2/10, moderate confidence.

What is the CRON stock price target?

Analyst target $2.56 reached (−23.5% from $3.35); no take-profit level is published. Analyst target $2.56 reached (−23.5%), stop $3.17 (−5.7%), A.R:R -3.9:1. Stop-loss: $3.17.

What are the risks of investing in CRON?

Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7); Earnings in 6 days (event risk).

Is CRON overvalued or undervalued?

Cronos Group Inc. Common Share trades at a P/E of 17.6 (forward -83.8). TrendMatrix value score: 4.3/10. Verdict: Hold.

What do analysts say about CRON?

9 analysts cover CRON with a consensus score of 4.1/5. Average price target: $3.

What does Cronos Group Inc. Common Share do?Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones...

Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission — accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Altria Group holds a 41.0% equity stake with board and governance rights.

Related stocks: IRWD (Ironwood Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · KNSA (Kiniksa Pharmaceuticals Interna) · ANIP (ANI Pharmaceuticals, Inc.) · SUPN (Supernus Pharmaceuticals, Inc.)
Home › Stocks › CRON

Latest news

Latest News

Kalkine.ca71d agoEarnings
MarketWatch78d ago
MarketWatch85d ago
Yahoo Finance72d agoEarnings
Kalkine Media77d ago
The Globe and Mail77d agoEarnings
Yahoo Finance84d ago
Yahoo Finance84d ago
MarketWatch84d ago
GuruFocus84d ago
MarketBeat84d ago
The Globe and Mail84d ago
Yahoo Finance84d ago
Seeking Alpha84d ago
Marketscreener.com84d agoEarnings
MarketBeat75d agoAnalyst
Kalkine Media73d ago
Seeking Alpha83d ago
DirectorsTalk Interviews83d ago
GuruFocus83d ago
Loading more...